UPDATE: Intrexon to Acquire Medistem for $26M

Intrexon Corporation XON today announced that it has entered into a definitive agreement to acquire, for approximately $26 million, San Diego-based Medistem, Inc. MEDS a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult stem cells that stimulate new blood vessel formation and are capable of generating different tissues including heart, brain, pancreas, liver, bone, cartilage and lung. Intrexon intends to employ its integrated synthetic biology platforms to engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs. See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Ex-Date
ticker
name
Dividend
Yield
Announced
Record
Payable
Posted In: NewsGuidanceDividendsContractsManagementGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!